08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Taiwan Liposome, Novartis sales and marketing update

On Dec. 18, 2013, Taiwan Liposome granted Novartis' Sandoz AG generics unit rights to commercialize AmBiL amphotericin B - a generic version of antifungal drug AmBisome from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) -...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Taiwan Liposome sales and marketing update

Taiwan Liposome launched AmBiL amphotericin B - a generic version of antifungal drug AmBisome from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) - in Taiwan following a shortage of AmBisome. In June, Gilead recalled 20...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

AmBiL regulatory update

Taiwan Liposome Co. Ltd. (GreTai:4152), Taipei, Taiwan   Product: AmBiL   Business: Infectious   Taiwan Liposome said Taiwan approved AmBiL to treat systemic fungal infection. AmBiL is a liposomal formulation of amphotericin B. Yung Shin...